TMCnet News
Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & ManufacturingCAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr. Singh will be responsible for overseeing Genocea’s manufacturing strategy including for GEN-009, the company’s personal neoantigen cancer vaccine candidate. “I’m delighted to welcome Narinder to the team here at Genocea at such an exciting time for the company as we advance GEN-009 into the clinic,” said Chip Clark, president and chief executive officer of Genocea. “Narinder’s experience in managing complex supply chains and leading high-performing teams will be invaluable as we seek to achieve our vision to cure cancer with next-generation vaccines.” Mr. Singh has more than 20 years of experience in process development, scale-up, technical operations and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Mr. Singh was Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals where he built an integrated drug product group to support Momenta’s expanding portfolio of biosimilars and novel biologics pipeline. Prior to Momenta, Mr. Singh was at Amgen where he played a key role in development of Amgen’s biologics-based pipeline and commercial drug products with a strong focus on process development, commercialization, manufacturing, and new technology development. Mr. Singh holds a B.Tech/M.Tech in Biochemical Engineering and Bitechnology from Indian Institute of Technology, Delhi, an M.S. in Chemical Engineering from the University of Houston, and an M.B.A. from UCLA Anderson School of Management. Equity Awards About Genocea Biosciences, Inc. For media: For investors: |